Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Freeline Therapeutics Holdings Plc Adss (FRLN)

Freeline Therapeutics Holdings Plc Adss (FRLN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,996
  • Shares Outstanding, K 64,972
  • Annual Sales, $ 0 K
  • Annual Income, $ -140,390 K
  • 60-Month Beta -0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade FRLN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.78
  • Most Recent Earnings -0.32 on 08/09/22
  • Next Earnings Date 11/08/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.42
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.51
  • Prior Year -0.86
  • Growth Rate Est. (year over year) +51.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6700 +14.85%
on 09/23/22
0.9500 -19.00%
on 08/25/22
-0.1604 (-17.25%)
since 08/23/22
3-Month
0.6700 +14.85%
on 09/23/22
1.1200 -31.29%
on 07/08/22
-0.1004 (-11.54%)
since 06/23/22
52-Week
0.6500 +18.38%
on 05/11/22
3.9700 -80.62%
on 09/24/21
-3.0805 (-80.01%)
since 09/23/21

Most Recent Stories

More News
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could Find Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an upward...

FRLN : 0.7695 (+11.94%)
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted...

FRLN : 0.7695 (+11.94%)
Here's Why Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could be Great Choice for a Bottom Fisher

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart...

FRLN : 0.7695 (+11.94%)
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Upgraded to Buy: Here's What You Should Know

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher...

FRLN : 0.7695 (+11.94%)
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON,...

FRLN : 0.7695 (+11.94%)
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a...

FRLN : 0.7695 (+11.94%)
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and...

FRLN : 0.7695 (+11.94%)
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 1.1200 (-2.61%)
ANGN : 1.0000 (+6.97%)
CKPT : 1.0600 (-0.93%)
EFTR : 0.5629 (+0.09%)
FRLN : 0.7695 (+11.94%)
GLYC : 0.5598 (-9.17%)
MGNX : 3.04 (+1.00%)
OCUP : 1.9600 (-4.39%)
PHAS : 0.7970 (-6.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. It is focused on AAV-based gene therapy targeting the liver. The company operates principally in Germany and the U.S. Freeline Therapeutics Holdings plc is headquartered in the U.K.

See More

Key Turning Points

3rd Resistance Point 0.9027
2nd Resistance Point 0.8362
1st Resistance Point 0.8029
Last Price 0.7695
1st Support Level 0.7031
2nd Support Level 0.6366
3rd Support Level 0.6033

See More

52-Week High 3.9700
Fibonacci 61.8% 2.7018
Fibonacci 50% 2.3100
Fibonacci 38.2% 1.9182
Last Price 0.7695
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar